First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)

Condition:   Esophageal Neoplasms
Interventions:   Biological: Pembrolizumab;   Drug: Placebo;   Drug: Cisplatin;   Drug: 5-FU
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified June 2017

http://ift.tt/2rzTE15